# Registry of Patients With AQP4+ NMOSD Treated With Alexion C5 Inhibitor Therapies

> **NCT05966467** · — · RECRUITING · sponsor: **Alexion Pharmaceuticals, Inc.** · enrollment: 122 (estimated)

## Conditions studied

- Neuromyelitis Optica Spectrum Disorder
- NMOSD
- AQP4+ NMOSD

## Interventions

_None listed._

## Key facts

- **NCT ID:** NCT05966467
- **Lead sponsor:** Alexion Pharmaceuticals, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** RECRUITING
- **Start date:** 2024-02-01
- **Primary completion:** 2030-03-01
- **Final completion:** 2030-03-01
- **Target enrollment:** 122 (ESTIMATED)
- **Last updated:** 2026-02-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05966467

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05966467, "Registry of Patients With AQP4+ NMOSD Treated With Alexion C5 Inhibitor Therapies". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT05966467. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*